Abstract
In 1996 a new disease was diagnosed. Ten years later it turned out to be an adverse reaction to some gadolinium-based contrast agents. Within 2 years it was clear that (1) it was only seen in patients with reduced renal function, particularly CKD 5 or on dialysis; (2) it was mainly in patients who had had gadodiamide; (3) the severity of the adverse reaction varies from a plaque to universal fibrosis; (4) the incidence varies from 3% (retrospective data) to 18% (prospective data); and (5) the higher the dose the higher the risk, but it is also seen after a single dose. Thanks to clear guidelines recommending that high-risk agents are not used in patients with poor renal function or on dialysis, the adverse reaction is no longer seen. Nephrogenic systemic fibroses was a reality for almost 20 years.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Thomsen HS, Dawson P, Tweedle M. Chapter 7: MR and CT contrast agents for perfusion imaging and regulatory issues. In: Brammer R, editor. MR and CT perfusion imaging: clinical applications and theoretical principles. Philadelphia, PA: Lippincott Williams and Wilkins; 2015. p. 85–102.
Morcos SK. Gadolinium chelates and stability. In: Thomsen HS, Webb JAW, editors. Contrast media: safety issues and ESUR guidelines. 3rd ed. Heidelberg: Springer; 2014. p. 175–80.
Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium—1997–2006–2016. Part 1. Acta Radiol. 2016;57:515–20.
Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:72–6.
Thomsen HS. Nephrogenic systemic fibrosis and gadolinium-based contrast media. In: Thomsen HS, Webb JAW, editors. Contrast media: safety issues and ESUR guidelines. 3rd ed. Heidelberg: Springer; 2014. p. 207–18.
Laurent S, van der Elst L, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;128–37.
Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 37°C. Investig Radiol. 2008;43:817–28.
Kimura J, Ishguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med. 2005;23:322–6.
Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium—1997–2006–2016. Part 2. Acta Radiol. 2016;57:643–8.
Thomsen HS, Leander P. Radiography with gadolinium-based contrast media. In: Thomsen HS, Webb JAW, editors. Contrast media: safety issues and ESUR guidelines. 3rd ed. Heidelberg: Springer; 2014. p. 193–200.
Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–8.
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–62.
Thomsen HS. T1-hyperintensity in the brain after multiple intravenous injections of gadolinium-based contrast agents. Acta Radiol. 2016;57:389–91.
Stacul F, Thomsen HS. Extracellular contrast media in perfusion imaging. In: Saremi F, editor. Perfusion imaging in clinical practice. A multimodality approach to tissue perfusion analyses. Philadelphia, PA: Wolters Kluwer; 2015. p. 205–16.
Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium (Gd) containing magnetic resonance contrast agent. Investig Radiol. 2008;43:141–4.
ESUR Contrast media guidelines version 9.0. www.esur-cm.org. Accessed 6 Sep 2017.
ACR, American College of Radiology. ACR Manual on Contrast Media Version 10.3; 2017. https://www.acr.org/Quality-Safety/Resources/Contrast-Manual. Accessed 6 Sep 2017.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nielsen, Y.W., Thomsen, H.S. (2021). NSF: Real or Hype?. In: Granata, A., Bertolotto, M. (eds) Imaging in Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-60794-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-60794-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-60792-0
Online ISBN: 978-3-030-60794-4
eBook Packages: MedicineMedicine (R0)